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In a quantitative study we have compared the serum 
level£" the time course and the photosensitizing capacity 
of a conventional crystalline 8-methoxypsoralen brand 
and an investigational liquid formula. Evidence is pre-
sented showing that the liquid preparation is superior 
to the crystalline form: it peaks earlier after ingestion, 
it produces higher and more reproducible serum concen-
trations and thus a more constant degree of photosensi-
tization, it is eliminated more rapidly from the blood, 
and it requires a lower UV-A dose for eliciting photosen-
sitivit.y reactions aiming at a reduction of the total cu-
mulative UV -A dose required for clearing psoriasis. 
It is generally assumed that the concentration of 8-methoxy-
psoralen (8-MOP) within the skin and other organs is directly 
related to its concentration in the serum [1], and that the 
concentration in the skin is relevant for the therapeutic success 
in photochemotherapy [2,3]. To produce reproducible thera-
peutic results 8-MOP is administered on a mg/ kg body weight 
basis and this dose is kept constant for each patient throughout 
therapy [4]. However , it has become evident that serum levels 
are highly variable in different patients [5-7] and that in a 
considerable number of patients the peak levels occw' later 
than the expected 2-111' period [2,5,7-9]. In addition, in their 
recent study, Menne et al [10] comparing 7 brands of 8-MOP 
have demonstrated a lru'ge interbrand vru'iation with regru'd to 
absolu te serum levels and the time for maximum concentration. 
Absorption, time coW'se pattern and peak serum levels of 8-
MOP apparently depend on the pharmaceutical preparation 
and there is some evidence that a liquid form of the drug may 
yield more constant blood levels [ll]. In this study we have 
compared the kinetics of a crystalline and a liquid preparation 
of 8-MOP focussing on the following issues: (1) the time interval 
between drug administration and peak serum level; (2) the time 
interval between drug administration and maximum photosen-
sitivity; (3) the relationship between serum level values and 
photosensitivity; (4) the ranges and the reproducibility of 8-
MOP serum levels under therapeutic conditions; and (5) the 
therapeutic efficacy and UV -A dose requirements for c1eal'ing 
psoriasis. 
MATERIALS AND METHODS 
Subjects 
One hundred and seventy-e ight psoria tic patients and 55 normal 
human volunteers wi th ages ranging from 23 to 67 (mean 38.5) were 
included in the study. Informed consent was obtained. 
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Drugs 
8-MOP was given orally in a dosage of 0.6 to 0.8 mg/ kg body weight. 
Two preparations of 8-MOP were used: (a) Oxsoralen (microcrystalline 
form in hard gelatine capsules) and (b) an investigational 8-MOP 
preparation (solution of 8-MOP in a mix ture of polyethylenglycol 400, 
1,2-propylenglycol and glycerin in soft gelatine capsules, 8-MOP liquid ). 
Both drug brands were obtained from Gero t Pharmazeutika, Vienna, 
Austria. 
UV Source and Photolestillg Procedure 
Phototoxicity tests were performed with a PUV A 500 irradiation 
unit (Messrs. Waldmann, Schwenningen, FRG) emitting a continuous 
spectrum between 320 and 390 nm (maximum at 365 nm) . P hototoxicity 
tests were carried out by inadiating 6 test areas on the back of each 
individual measming 4 em in diameter with increasing UV-A doses: for 
skin types I and 110.5; 1; 2; 3; 4 and 5 J / cm2 and for skin types III and 
IV 1.5; 2; 3; 5; 7 and 9 J /cm2 . Erythema readings were made after 72 hr 
using a + 1 to +4 scale in order to determine the minimal phototoxocity 
dose (MPD) [4]. 
B-MOP Assay 
Serum levels were determined in 751 samples by means of high 
pressm e liquid c1u'omatography (HPLC): 
Extraction 
To 1 ml samples of serum 0.3 ml of the in tel'l1al standard (150 Ilg 5-
methoxypsoralen dissolved in 100 ml of a 1:1 mixture of chloroform and 
carbon tetrachloride) were added a nd sha ken for 1 min at room tem-
perature. After centrifugation for 10 min at 1500 g the clear organic 
phase was transferred into another tube and evaporated at 30°C under 
dry nitrogen. Prior to HPLC the residue was redisso lved in 200 III of 
the mobile phase (70:30 methanol: odium-acetate buffer (pH 5.0) and 
injected over a 50 III loop on the column. 
Chroll/.atography 
A high-pressure liquid chromatograph (Spectra P hy ics 8000 HPLC) 
with a UV detector (Schoeffe l 770, operating at 300 nm) was used for 
the analysis. The stationru'y phase was a RP 18 column (Hibru' Merck; 
5°; 250 x 4 mm) a nd the mobile phase was a mixture of methanol a nd 
sodium acetate buffer (pH 5.0) (70:30). The flow rat.e of the system was 
1.6 ml/min. Under these condi tions the retention time of 8-MOP is 150 
sec, the retention t ime of the internal standard 180 sec. The detection 
limi t lies at a bout 2 ng/ ml serum. For relative recovery 97 ± 5.2% was 
found. As determined by repeated assays the standard deviation at a 
concentra tion of 40 ng/ ml was ±7.5%. 
Con.trols 
Serum samples with known 8-MOP levels (34 sera) and samples 
without 8-MOP (68 sera) served as controls for each determination run. 
Serull/. Level and Phototoxicily Profiles 
This study comprises the data of 20 patients receiving Oxsoralen and 
of 7 pa tients with 8-MOP- liquid. For serum level determinations blood 
was taken at 30 min, I, 1'12, 2, 2'/2, 3, 4, 6, 8, 12, and 24 hI' after a single 
dose of 8-MOP. P hototoxicity tests were carried out in the patien.ts 
receiving Oxsoralen at I, 2, 3, and 4 h1' and at 1, 2, 3, 4, 5, and 6 hI' 111 
patients receiving 8-MOP-liquid. Readings were made after 72 hJ' ruld 
the maximum test reaction was defined as the reaction which shows 
the lowest minimal phototoxicity dose (MPD) and the highest grade of 
erythema readings out of a ll tests. An example is shown in T able I. In 
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3 patients on Oxsoralen and in 2 on 8-MOP-liquid the whole profile 
was performed twice. 
Serum Levels under Therapeutic Conditions 
Seru m levels were determined 2 hr after ingestiorLof Qxsoralen in 34 
patients and 1 hr after the administration of 8-MOP-liquid il1'Tpatients. 
Five to 15 determinations were carried out in each patient on different 
days. A total number of 232 sera with Oxsoralen and of 87 with 8-MOP-
liquid was evaluated. To obtain comparable results the conditions of 
drug administration (time of day, preceding food intake) were kept 
constant for each patient. 
MPD Determination with Both Drug Brands in the Same Patient 
In 28 patients the MPD was determined with bot h Oxsoralen and 8-
MOP-liquid on different days. The phototesting was performed at 2 hr 
after Oxsoralen administration and at 1 hr after 8-MOP-liquid. Ery-
thema readings were performed after 72 hr. The MPD va lues as 
expressed in J /cm2 obtained with both drugs were compared s tatisti-
caUy by using the t-test. 
Photochemotherapy 
Patients with severe widespread psoriasis were treated with either 
Oxsoralen (134 patients) or 8-MOP-Liquid (44 patients) according to 
standard photochemotherapy schedules (four times per week until 
complete clearing of psoriasis) [4). The patients were randomly assigned 
to either therapy and there was no difference in the overaU distribution 
of skin type and complexion. At t he end of the clearing phase the 
number of treatments and days required for clearing, and the total 
cumulative UV-A doses were compared statis tically (t-test). 
RESULTS 
Serum Levels 
Oxsoralen: Low amounts of 8-MOP were found in some of 
the sera as early as 30 min after dl"Ug administration (Fig 1). 
The means of the serum levels clearly showed a peak at 4 hr 
after drug intake (Fig 1) . In 7 patients amounts of up to 60 ng/ 
ml were still detectable after 24 hr. Within the 24-hr period, a 
measurable serum level could be detected in all patients at a 
given time, t hough in some 8-MOP occurred in the serum as 
late as after 3 to 6 hr. This prolonged a bsorption time, however, 
did not result in longer lasting serum levels as no 8-MOP was 
fou nd after 24 hr in these patients. 
8-MOP-liquid: 30 min after drug administration the mean 
serum concentration reached levels which were more than twice 
as high as the mean levels at th e time of maximum concentra-
tion after Oxsoralen intake. By 1 hr the peak serum concentra-
tion was reached showing a more than three-fold level as with 
Oxsoralen at its peak. A relatively steep slope was found after 
2 hr and by 4 hr the levels sank to approximately half of the 
Oxsoralen values indicating a more rapid elimination. No mea-
surable amounts were found after 24 hr (Fig 1) . 
Photosensitivity 
Oxsoralen: Positive phototoxicity tests were found in 8 of 23 
patients after 1 hr and in 15 of 23 patients after 2 hr. After 3 hr 
TABLE 1. Example of a phototox icity profile in a shin type II patient 
after Oxsoralen administration 
J /cm2 0.5 1.0 2.0 3.0 4.0 5.0 
Time 
after 
B· MOP 
intake 
(h .. ) 
1 +" + 
2 +" + +2 + 2 
3" + " + +2 +2 +3 +3 
4 +" + +2 + 3 +3 
" The lowest UV -A dose which produces a visible erythema is defined 
as minimal phototox icity dose (MPD): 
" Maximum test reaction: lowest UV -A dose of aU 4 tests for e liciting 
the MPD and highest grade of erythema readings. 
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all 23 patients exhibited photosensitivity. Most of the patients 
had their maximum test reaction either at 2 hr (7 of 23 patients) 
or at 4 hr (10 of 23 patients) (Fig 2). 
8-MOP-liquid: Between 1 and 2 hr after drug intake all 9 
patients exhibited their maximum test reaction, and the tests 
remained positive in all subjects up to 4 hr and, in 6 of them, up 
to 6 hr. 
Correlation of Peah Serum L evels and Maximum Test 
Reaction 
Oxsoralen: The time after which the peak serum level was 
reached appeared highly variable. The largest group comprising 
8 patients had its peak at 4 hr. Unexpected ly in 2 patients the 
peak occurred as late as after 6 ill". As shown in Fig 2, the 
maximum test reaction did not a1ways exactly coincide with the 
·peak serum level. This was probably due to the fact that 
phototoxicity tests h ad been carried out only at full hours a nd 
some patients acquired their peak level at a time in between. 
However, if only those serum levels were considered, which had 
been determined at full hours, there was a defmite correlation 
between the highest serum level and the maximal test reaction 
in 18 (78%) of the 23 tests. 
8-MOP-liquid: With this preparation the results were re-
markably constant. All subjects had their peak levels between 
1 and 2 hr (Fig 2). The maximum test reaction showed a high 
rate of coincidence (89%) with the maximum serum level; only 
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one patient who had his peak level at 2 hl' exhibited the 
maximum test reaction at 4 hr (Fig 2). 
S erum L evels under Therapeutic Conditions 
Oxsoralen: The serum levels 2 Ill' after drug intake varied 
considerably and in an unpredictable pattern, on differen t days 
in the same subj ect. A high level could drop to zero in the same 
patient on the following day when Oxsoralen was read minis· 
tered and, reversely, a low or zero level could go up to high 
levels (Fig 3). This phenomenon occmred independently of the 
time of drug administration and of food intake. In 232 deter· 
minations the levels were 114 ± 119 ng/ml (x ± s) the highest 
level being 560 ng/ ml serum. 
8·MOP·liquid: Since the serum profiles had revealed that 8· 
MOP·liquid peaks a t 1 hr, PUV A treatments were given at that 
time. Thus for determination of the serum levels under thera· 
peutic conditions the l·hr in terval was chosen . At this time 8· 
MOP·liquid yielded much more constant levels, although there 
was also some variation in the sam e patient when tests were 
performed on different days (Fig 3). Zero levels were hardly 
encountered. As with Oxsoralen no variations were found which 
could have been attributed to the t ime of drug administratiun 
or to food intake. In 87 determinations the levels were 305 ± 
184 ng/ ml (x ± s) the high est levels r eached being 850 ng/ ml. 
The mean levels of 8·MOP·liquid were thus 2.7 times higher 
than the mean levels of Oxsoralen (p < 0.01). 
Comparison of Serum Levels of Both Drug Bra.nds 
If the sera were grouped in to subclasses according to ranges 
of 8·MOP concentration (10, 10-199, 200-399, 400-599, 600 ng/ 
ml) there was a definite shift to higher levels in the 8·MOp· 
liquid group (Table II). 
Controls 
Sera hom patients without S·MOP were constantly negative 
and sera with lmown 8-MOP levels r eproducibly gave identical 
results within t he range of the sensitivity of the method. 
MPD Determination with Both Drug Brands in the Same 
Patients 
Twenty·eigh t patients were tested with both drug brands. 
The UY·A dose necessary for eliciting the MPD reaction was 
significantly reduced by approximately 25% with 8·MOP-liquid 
(tested 1 hr after intake) as compal'ed with Oxsoralen (tested 2 
hI' after intake) (3.4 ± 2.4 J /cm2 vs. 4.8 ± 3.4 J /cm2; p < 0.01). 
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FIG 3 Examples of the variation pattern of 8·MOP serum levels in 
2 pa tients undergoing standard PUV A therapy (drug administration 
and UV·A exposure 4 times a week) wi th e ither Oxsoralen or 8·MOP· 
liquid . 
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Photochemotherapy 
The data of 134 patients on Oxsoralen-photochemotherapy 
and of 44 patients on 8·MOP·liquid·photochemotherapy r e-
vealed a significant reduction (40%) of t he total cumulative UV· 
A dose for the latter group. The number of exposures a nd th e 
dmation of treatment, however , appeared to be in the same 
range (Ta ble Ill). 
DISCUSSION 
Several recen t reports have shown that 8·MOP blood levels 
and t he time-course r elationship vary considerably with the 
drug brand used [2,5,10-12]. Consequently, th e results ofPUVA 
treatment of psoriasis differ with r egard to total UV·A dose, 
number of exposures and dmation of treatment [10]. There is 
evidence that t he specific preparation formula of 8·MOP 
strongly influences speed and capacity of absorpt ion and thus 
bioavaila bility in t he skin. Schmid et al [13] with isotope studies 
have demonstrated t hat orally a dministered crystalline 8·MOP 
exhibits a marked, saturable first· pass effect which means that 
small variations in the dose and/ or rate of a bsorption cause 
great differences in the systemic bioavailability. They also 
found that a solution of 8·MOP avoid t he influence of the first· 
pass effect and thus yields higher a nd perhaps more constant 
serum levels. 
In the present investigation we have compar ed the serum 
levels, the time course, and th e photosensitizing capacity of a 
conventional crystalline 8·MOP brand (Oxsoralen) and an in· 
vestigationalliquid formula (8·MOP·liquid). The resul ts of this 
study clearly demonstrate that 8·MOP-liquid is superior to 
Oxsoralen. 
As revealed by combined 24·111' proftl es of serum levels and 
phototoxicity testing, there exists a good correlation for both 
drug preparations between the 8·MOP serum level and the 
degree of skin sensitization and this is in agreement with earlier 
observations [2,3,5,9,14,15]. 
R epeated profile studies in 5 patients suggest that, despite 
variations in the absolute values from one day to anoth er, the 
tim e of peak levels and of the maximum test reaction remains 
constant for each subject. However, the number of subjects 
may be too small to exclude m ere coincidence. Although in 
some psoriasis patients an obvious lack of correlation of the 
therapeutic r esponse and the peak plasma levels has been noted 
[8,16,17], we have observed a defini te improvemen t of PUV A 
therapy in a considerable number of patients when irradiation 
time was switched from 2 to 3 hI' after Oxsoralen administration 
with the intention to meet the time of maximum serum levels 
of this drug preparation. S imilarly, treatment resul ts could be 
markedly improved in poor PUV A responders with low serum 
levels when patients were switched to an 8·MOP·liquid sched· 
ule. 
TABLE II. Ranges of S-MOP serum levels" 
8·MOP Oxsoralen a·MOP· liquid 
(ng/ ml) (% of sera) (% of sera) 
< 10 17.4 3.4 
10-299 73.4 46.0 
300-599 9.2 47.1 
>600 0 3.4 
" Determined 2 hI' after Oxsoralen and 1 h I' after 8·MOP·liqu id 
administration. 
TABLE III. Oxsora.len vs. 8·MOP-liquid/ PUVA treaim ent: results of 
clearing phase 
Oxsoralen 
8-MOP-liquid 
Duration of 
treatment 
(days) 
29. 1 ± 18.2 
28.2 ± 15.7 n.s. 
No. of 
t.reatments 
14.5 ± 8.2 
14.2 6.7 n.s. 
Total UV· A 
dose (J /cm' ) 
I06±Jl5 <002 
62 ± 59 P . 
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8-MOP-liquid proved to yield higher (up to more than 3-fold) 
and more reproducible serum levels. Variations of serum con-
centrations did occur in the same patients on different days, 
but not to the extent found for Oxsoralen. Moreover, the time 
of peak serum levels on average 1 hr after drug ingestion, 
appears to be more constant for 8-MOP liquid than Oxsoralen. 
Although not evaluated statistically there seems to be no influ-
ence of preceding or concomitant food intake and/or of the 
time of the day on drug serum levels. Because of a higher 
average serum concentration of 8-MOP-liquid one can expect a 
higher 8-MOP concentration in the skin and this is in keeping 
with the observation that lower UV -A doses al'e necessary to 
elicit a comparable phototoxic reaction: in patients who had 
been phototested with both drug brands the MPD values for 8-
MOP-liquid proved to be significantly lower. Since the MPD 
and thus the initial therapeutic UV -A dose requirements are 
lower, dose increments during therapy can start from a lower 
dose level. This leads to a reduction by approximately 40% of 
the total cumulative UV-A dose required for clearing psoriasis. 
Moreover, the liquid prepamtion aims at a more constant 
therapeutic result which in turn seems to increase the ability to 
control both, drug and UV more carefully. As potential long-
term side effects (ageing, carcinogenesis) presumably are re-
lated to total lifetime PUV A exposure (see reference 18) such 
improved control should contribute in reducing the risk of 
adverse reactions by reducing PUV A doses for clearing and 
maintenance in patients who req uire repeated long-term treat-
ment. 
As indicated by the time-course studies, 8-MOP-liquid is 
eliminated more rapidly from the blood and this might reduce 
the hazard of undesired photosensitivity reactions after treat-
ment. 
In summary, the use of 8-MOP-liquid in photochemotherapy 
has several advantages over common crystalline formulas: (1) 
it peaks in the serum at 1 hr after ingestion and thus leads to a 
higher patient's acceptance, as it reduces the waiting period 
between drug ingestion and treatment; (2) it produces higher 
and more reproducible serum levels providing a more constant 
degree of Rhotosensitization; (3) it is eliminated more rapidly 
from the serum; (4) it requires a smaller UV -A radiant exposure 
for eliciting photosensitivity reactions: preliminary data indi-
cate that the total cumulative UV -A dose required for clearing 
psoriasis may be considerably reduced; and (5) it allows a more 
careful control of the PUV A reactions and may thus lead to a 
reduction of the total lifetime PUV A exposure in long-term 
treatment. 
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